RU2006105646A - Производные азепина в качестве фармацевтических агентов - Google Patents

Производные азепина в качестве фармацевтических агентов Download PDF

Info

Publication number
RU2006105646A
RU2006105646A RU2006105646/04A RU2006105646A RU2006105646A RU 2006105646 A RU2006105646 A RU 2006105646A RU 2006105646/04 A RU2006105646/04 A RU 2006105646/04A RU 2006105646 A RU2006105646 A RU 2006105646A RU 2006105646 A RU2006105646 A RU 2006105646A
Authority
RU
Russia
Prior art keywords
optionally substituted
heteroaryl
heterocyclyl
ring
alkyl
Prior art date
Application number
RU2006105646/04A
Other languages
English (en)
Russian (ru)
Inventor
Ричард МАРТИН (US)
Ричард Мартин
Те-Линь ВАН (US)
Те-Линь ВАН
Брентон Т. ФЛЭТТ (US)
Брентон Т. ФЛЭТТ
С о-Хой ГУ (US)
Сяо-Хой ГУ
Original Assignee
Экселиксис, Инк. (Us)
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. (Us), Экселиксис, Инк. filed Critical Экселиксис, Инк. (Us)
Publication of RU2006105646A publication Critical patent/RU2006105646A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2006105646/04A 2003-07-23 2004-07-23 Производные азепина в качестве фармацевтических агентов RU2006105646A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23
US60/489,854 2003-07-23

Publications (1)

Publication Number Publication Date
RU2006105646A true RU2006105646A (ru) 2007-09-10

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006105646/04A RU2006105646A (ru) 2003-07-23 2004-07-23 Производные азепина в качестве фармацевтических агентов

Country Status (14)

Country Link
US (1) US8466143B2 (https=)
EP (1) EP1648408A4 (https=)
JP (1) JP4679517B2 (https=)
KR (1) KR20060052867A (https=)
CN (1) CN1852748A (https=)
AU (1) AU2004259009A1 (https=)
BR (1) BRPI0412262A (https=)
CA (1) CA2532798C (https=)
CR (1) CR8258A (https=)
EC (1) ECSP066392A (https=)
IL (1) IL173287A0 (https=)
NO (1) NO20060871L (https=)
RU (1) RU2006105646A (https=)
WO (1) WO2005009387A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
US20080161289A1 (en) 2005-03-14 2008-07-03 Glaxo Group Limited Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
AU2009308706C1 (en) 2008-10-31 2016-01-21 Medivation Technologies, Inc. Pyrido (4,3-b) indoles containing rigid moieties
WO2010051503A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
SG176100A1 (en) 2009-05-22 2011-12-29 Abbott Lab Modulators of 5-ht receptors and methods of use thereof
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
KR101770979B1 (ko) 2010-05-21 2017-08-24 애브비 인코포레이티드 5­ｈｔ 수용체의 조절제 및 이의 사용방법
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
CN103476417A (zh) 2011-02-18 2013-12-25 梅迪维新技术公司 治疗糖尿病的化合物和方法
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
CA2968434A1 (en) 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CN107438612A (zh) * 2014-12-22 2017-12-05 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
AU2016238523A1 (en) 2015-03-26 2017-11-09 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
BR112018073460A2 (pt) * 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
MX2018014034A (es) * 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物
MA51679A (fr) * 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
UA128348C2 (uk) 2018-01-26 2024-06-19 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AU8766498A (en) * 1997-08-04 1999-02-22 Amgen, Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
SG121853A1 (en) 1999-06-18 2006-05-26 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス， インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体

Also Published As

Publication number Publication date
JP2006528637A (ja) 2006-12-21
EP1648408A1 (en) 2006-04-26
CA2532798C (en) 2013-02-19
CR8258A (es) 2006-08-30
KR20060052867A (ko) 2006-05-19
CN1852748A (zh) 2006-10-25
US8466143B2 (en) 2013-06-18
WO2005009387A2 (en) 2005-02-03
AU2004259009A1 (en) 2005-02-03
US20070015746A1 (en) 2007-01-18
JP4679517B2 (ja) 2011-04-27
WO2005009387A3 (en) 2006-03-02
BRPI0412262A (pt) 2006-09-19
CA2532798A1 (en) 2005-02-03
NO20060871L (no) 2006-04-24
EP1648408A4 (en) 2006-11-29
ECSP066392A (https=) 2007-01-26
IL173287A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
RU2006105646A (ru) Производные азепина в качестве фармацевтических агентов
JP2006528637A5 (https=)
JP4217968B2 (ja) 三環式複素環誘導体化合物およびその化合物を有効成分とする医薬
CN102197038B (zh) 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物
CN119033782B (zh) 抗血小板药物和其用途
JP2011512361A5 (https=)
AU2007223342A1 (en) Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors
CA2886710A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
EP1161434A1 (fr) Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
AU2007311983A1 (en) An Alzheimer' s disease progression inhibitor containing heterocyclic compound
CZ20014178A3 (cs) Nové deriváty a analogy galanthaminu
JP5898233B2 (ja) 置換された水素化チエノ−ピロロ［３，２−ｃ］ピリジン、リガンド、医薬組成物及び上記を使用するための方法
FR2859208A1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2745503A1 (fr) Nouveaux derives d'oxime du 3,5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, et procede de preparation
EP4330255A1 (en) Processes for the synthesis of valbenazine
KR0183395B1 (ko) 2,4,8-삼치환된 3H,6H-1,4,5a,8a-테트라아자아세나프틸렌-3,5-(4H)-디온화합물, 및 이의 제조방법
AU2021348704A1 (en) Fused tricyclic derivative and pharmaceutical application thereof
IE44809B1 (en) Bis-penicillanoyloxy-alkanes
CZ99394A3 (en) 2,6-disubstituted 4-quinolinyl-dihydropyridines, process of their preparation , medicaments containing said substances, process of their preparation and the use of said compounds
KR20220015426A (ko) 캡시드 조립 조절제로서의 융합 복소환 유도체
WO1993012120A1 (fr) Derive de pyrazolothiazolopyrimidine
JP2971901B2 (ja) トリアゾロ―１，４―ジアゼピン系化合物
CA2502488A1 (fr) Nouveaux derives de [1,4]benzodioxino[2,3-e]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2024026350A1 (en) Selective opioid receptor agonists and antagonists
CA2101933A1 (en) Neuroprotectant agents

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100203